| Year |
Citation |
Score |
| 2023 |
Ou L, Liu S, Wang H, Guo Y, Guan L, Shen L, Luo R, Elder DE, Huang AC, Karakousis G, Miura J, Mitchell T, Schuchter L, Amaravadi R, Flowers A, ... ... Xu X, et al. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. Ebiomedicine. 92: 104614. PMID 37229906 DOI: 10.1016/j.ebiom.2023.104614 |
0.698 |
|
| 2022 |
Ou L, Wang H, Huang H, Zhou Z, Lin Q, Guo Y, Mitchell T, Huang AC, Karakousis G, Schuchter L, Amaravadi R, Guo W, Salvino J, Herlyn M, Xu X. Preclinical platforms to study therapeutic efficacy of human γδ T cells. Clinical and Translational Medicine. 12: e814. PMID 35731974 DOI: 10.1002/ctm2.814 |
0.685 |
|
| 2021 |
Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, ... ... Xu X, et al. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. Journal For Immunotherapy of Cancer. 9. PMID 34937742 DOI: 10.1136/jitc-2021-003339 |
0.692 |
|
| 2021 |
Huang L, Guo Y, Liu S, Wang H, Zhu J, Ou L, Xu X. Targeting regulatory T cells for immunotherapy in melanoma. Molecular Biomedicine (Online). 2: 11. PMID 34806028 DOI: 10.1186/s43556-021-00038-z |
0.712 |
|
| 2021 |
Guo Y, Wang H, Huang L, Ou L, Zhu J, Liu S, Xu X. Small extracellular vesicles-based cell-free strategies for therapy. Medcomm. 2: 17-26. PMID 34766134 DOI: 10.1002/mco2.57 |
0.694 |
|
| 2021 |
Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, ... ... Xu X, et al. Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Research. PMID 34462276 DOI: 10.1158/0008-5472.CAN-20-1496 |
0.307 |
|
| 2021 |
Ou L, Wang H, Liu Q, Zhang J, Lu H, Luo L, Shi C, Lin S, Dong L, Guo Y, Huang L, Zhu J, Yin X, Huang AC, Karakousis G, ... ... Xu X, et al. Dichotomous and stable gamma delta T-cell number and function in healthy individuals. Journal For Immunotherapy of Cancer. 9. PMID 34011536 DOI: 10.1136/jitc-2020-002274 |
0.702 |
|
| 2020 |
Dong D, Chen S, Feng C, Xiong H, Xu X. NB-UVB Induces Melanocytic Differentiation of Human Hair Follicle Neural Crest Stem Cells. Annals of Dermatology. 32: 289-297. PMID 33911756 DOI: 10.5021/Ad.2020.32.4.289 |
0.311 |
|
| 2020 |
Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, ... ... Xu X, et al. PPT1 Inhibition enhances the anti-tumor activity of anti-PD-1 antibody in melanoma. Jci Insight. PMID 32780726 DOI: 10.1172/Jci.Insight.133225 |
0.377 |
|
| 2020 |
Straker RJ, Modi MB, Elder DE, LiVolsi VA, Fraker DL, Xu X, Karakousis GC. A Case of Tumor-To-Tumor Metastasis of Cutaneous Malignant Melanoma. Journal of Cutaneous Pathology. PMID 32740977 DOI: 10.1111/Cup.13829 |
0.374 |
|
| 2020 |
Modi MB, Gimotty PA, Ming ME, Jariwala N, Elenitsas R, Miller C, Chu EY, Lindner H, Moshiri AS, Schwartz LE, Lal P, Reyes MC, Elder DE, Xu X. Urethral involvement is associated with higher mortality and local recurrence in vulvar melanoma: a single institutional experience. Human Pathology. PMID 32702401 DOI: 10.1016/J.Humpath.2020.07.017 |
0.319 |
|
| 2020 |
Teh JL, Erkes DA, Cheng PF, Tiago M, Wilski NA, Field CO, Chervoneva I, Levesque MP, Xu X, Dummer R, Aplin AE. Activation of CD8+ T cells contributes to anti-tumor effects of CDK4/6 inhibitors plus MEK inhibitors. Cancer Immunology Research. PMID 32661093 DOI: 10.1158/2326-6066.Cir-19-0743 |
0.401 |
|
| 2020 |
Dong D, Xu X, Feng C, Xiong H, Pan Z. Comparison of responses of melanocyte lineages from p75(+) and p75(-) human scalp-derived neural crest stem cells under phototherapy. Lasers in Medical Science. PMID 32607713 DOI: 10.1007/S10103-020-03047-6 |
0.312 |
|
| 2020 |
Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, Webster MR, Kugel CH, Ecker BL, Caino MC, Kossenkov AV, Tang HY, Frederick DT, Flaherty KT, Xu X, et al. Changes in Aged Fibroblast Lipid Metabolism Induce Age-dependent Melanoma Cell Resistance to Targeted Therapy Via the Fatty Acid Transporter FATP2. Cancer Discovery. PMID 32499221 DOI: 10.1158/2159-8290.Cd-20-0329 |
0.309 |
|
| 2020 |
Shannon AB, Song Y, Xu X, Karakousis GC. Age and Melanocytic Lesions. Surgical Oncology Clinics of North America. 29: 369-386. PMID 32482314 DOI: 10.1016/J.Soc.2020.02.005 |
0.318 |
|
| 2020 |
Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V, Ngiow SF, Khan O, Huang YJ, Yan P, Nzingha K, Xu W, Amaravadi RK, Xu X, et al. Developmental Relationships of Four Exhausted CD8 T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity. PMID 32396847 DOI: 10.1016/J.Immuni.2020.04.014 |
0.34 |
|
| 2020 |
Guo Y, Zhang X, Zeng W, Zhang J, Cai L, Wu Z, Su J, Xiao Y, Liu N, Tang L, Xu X, Chen X, Peng C. TRAF6 activates fibroblasts to cancer-associated fibroblasts (CAFs) through FGF19 in tumor microenvironment to benefit the malignant phenotype of melanoma cells. The Journal of Investigative Dermatology. PMID 32275977 DOI: 10.1016/J.Jid.2020.03.950 |
0.439 |
|
| 2020 |
Wang G, Wu M, Durham AC, Radaelli E, Mason NJ, Xu X, Roth DB. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma. Plos One. 15: e0229728. PMID 32210430 DOI: 10.1371/Journal.Pone.0229728 |
0.319 |
|
| 2020 |
Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, Xie Z, Weng L, Guo J, Li H, Ma F, Chen X, Zhao S, Su J, Yang N, ... ... Xu X, et al. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell. 37: 324-339.e8. PMID 32183950 DOI: 10.1016/J.Ccell.2020.02.006 |
0.341 |
|
| 2020 |
Shah PD, Huang ACC, Xu X, Zhang PJ, Orlowski R, Matlawski T, Shea J, Cervini A, Amaravadi RK, Tchou JC, Schuchter LM, Wherry EJ, Linette GP, Mick R, Kulikovskaya I, et al. Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma. Journal of Clinical Oncology. 38: 10035-10035. DOI: 10.1200/Jco.2020.38.15_Suppl.10035 |
0.335 |
|
| 2020 |
Karagounis IV, Pierini S, François N, Thomas C, Xu X, Koumenis C, Facciabene A, Maity A. Abstract 6509: Hypofractionated radiotherapy as a vaccine in combination with the TLR7/8 agonist resiquimod leads to significant abscopal tumor response and persistence antitumor immunity Cancer Research. 80: 6509-6509. DOI: 10.1158/1538-7445.Am2020-6509 |
0.39 |
|
| 2020 |
Sun Q, Katehis I, Lee W, Mohri Y, Takeo M, Lim C, Xu X, Myung P, Atit R, Taketo M, Moubarak R, Schober M, Osman I, Gay D, Saur D, et al. 664 Oncogenic melanocyte stem cells, driven by regenerative niche signals, give rise to heterogeneous melanoma resembling human melanoma Journal of Investigative Dermatology. 140: S90. DOI: 10.1016/J.Jid.2020.03.676 |
0.349 |
|
| 2019 |
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, ... Xu X, et al. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell. PMID 31836388 DOI: 10.1016/J.Molcel.2019.11.009 |
0.357 |
|
| 2019 |
Sun Q, Lee W, Mohri Y, Takeo M, Lim CH, Xu X, Myung P, Atit RP, Taketo MM, Moubarak RS, Schober M, Osman I, Gay DL, Saur D, Nishimura EK, et al. A novel mouse model demonstrates that oncogenic melanocyte stem cells engender melanoma resembling human disease. Nature Communications. 10: 5023. PMID 31685822 DOI: 10.1038/S41467-019-12733-1 |
0.385 |
|
| 2019 |
Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C, Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Schuchter LM, et al. Anti-CTLA4 activates intratumoral NK cells and combined with IL15/IL15R-alpha complexes enhances tumor control. Cancer Immunology Research. PMID 31239316 DOI: 10.1158/2326-6066.Cir-18-0386 |
0.399 |
|
| 2019 |
Yun SJ, Liu S, Buckley M, Wang T, Jin S, Karakousis G, Peters MG, Elder DE, Gimotty PA, Xu X. Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma. Human Pathology. PMID 30965022 DOI: 10.1016/J.Humpath.2019.03.008 |
0.378 |
|
| 2019 |
Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine. PMID 30804515 DOI: 10.1038/S41591-019-0357-Y |
0.352 |
|
| 2019 |
Xu N, Li J, Gao Y, Zhou N, Ma Q, Wu M, Zhang Y, Sun X, Xie J, Shen G, Yang M, Tu Q, Xu X, Zhu J, Tao J. Apoptotic cell-mimicking gold nanocages loaded with LXR agonist for attenuating the progression of murine systemic lupus erythematosus. Biomaterials. 197: 380-392. PMID 30703743 DOI: 10.1016/J.Biomaterials.2019.01.034 |
0.311 |
|
| 2019 |
Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, Onorati A, Kalavacharla A, Kim T, Zhen CJ, Kadri S, Segal JP, Gimotty PA, Davis LE, Amaravadi RK. Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30635337 DOI: 10.1158/1078-0432.Ccr-18-2204 |
0.309 |
|
| 2019 |
Villanueva J, Echevarria-Vargas IM, Reyes-Uribe PI, Guterres A, Ronghe A, Burgos DMZ, Liu Q, Xu X, Speicher DW. Abstract 3842: Co-targeting BET and MEK as salvage therapy for MAPKi and checkpoint inhibitor resistant melanoma Cancer Research. 79: 3842-3842. DOI: 10.1158/1538-7445.Am2019-3842 |
0.365 |
|
| 2018 |
Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker B, Yang R, Feltcher C, Peng K, Feng C, ... ... Xu X, et al. Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 9: 5426. PMID 30575721 DOI: 10.1038/S41467-018-07126-9 |
0.371 |
|
| 2018 |
Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discovery. PMID 30563872 DOI: 10.1158/2159-8290.Cd-18-0348 |
0.325 |
|
| 2018 |
Parekh V, Sobanko J, Miller CJ, Karakousis G, Xu W, Letrero R, Elenitsas R, Xu X, Elder DE, Amaravadi R, Schuchter LM, Nathanson KL, Wilson MA, Chu EY. NRAS Q61R and BRAF G466A Mutations in Atypical Melanocytic Lesions Newly Arising in Advanced Melanoma Patients Treated with Vemurafenib. Journal of Cutaneous Pathology. PMID 30552700 DOI: 10.1111/Cup.13401 |
0.317 |
|
| 2018 |
Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, ... ... Xu X, et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discovery. PMID 30442709 DOI: 10.1158/2159-8290.Cd-18-0706 |
0.346 |
|
| 2018 |
Sarvi S, Crispin R, Lu Y, Zeng L, Hurley TD, Houston DR, von Kriegsheim A, Chen CH, Mochly-Rosen D, Ranzani M, Mathers ME, Xu X, Xu W, Adams DJ, Carragher NO, et al. ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH Melanoma-Initiating Cells. Cell Chemical Biology. PMID 30293938 DOI: 10.1016/J.Chembiol.2018.09.005 |
0.394 |
|
| 2018 |
Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 7: e1468956. PMID 30288340 DOI: 10.1080/2162402X.2018.1468956 |
0.319 |
|
| 2018 |
Kaur A, Ecker BL, Douglass SM, Kugel CH, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, ... ... Xu X, et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discovery. PMID 30279173 DOI: 10.1158/2159-8290.Cd-18-0193 |
0.357 |
|
| 2018 |
Zhao S, Wu L, Kuang Y, Su J, Luo Z, Wang Y, Li J, Zhang J, Chen W, Li F, He Y, Tao J, Zhou J, Xu X, Peng C, et al. Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression. International Journal of Oncology. PMID 30272281 DOI: 10.3892/Ijo.2018.4579 |
0.337 |
|
| 2018 |
Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank C, Van De Wiel B, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, Mitchell T, Menzies AM, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29945191 DOI: 10.1093/Annonc/Mdy226 |
0.325 |
|
| 2018 |
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, ... ... Xu X, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Embo Molecular Medicine. PMID 29650805 DOI: 10.15252/Emmm.201708446 |
0.348 |
|
| 2018 |
Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, ... ... Xu X, et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563139 DOI: 10.1158/1078-0432.Ccr-17-2773 |
0.359 |
|
| 2018 |
Sinnamon AJ, Sharon CE, Song Y, Neuwirth MG, Elder DE, Xu X, Chu EY, Ming ME, Fraker DL, Gimotty PA, Karakousis GC. The Prognostic Significance of Tumor-Infiltrating Lymphocytes for Primary Melanoma Varies by Sex. Journal of the American Academy of Dermatology. PMID 29518458 DOI: 10.1016/J.Jaad.2018.02.066 |
0.319 |
|
| 2018 |
Zhang B, Strauss R, Moran A, Zhang P, Xu X. Atypical Intramucosal Melanocytic Cell Proliferation in Colorectal Mucosa American Journal of Clinical Pathology. 150. DOI: 10.1093/Ajcp/Aqy090.042 |
0.327 |
|
| 2018 |
Sun Q, Lee W, Takeo M, Lim C, Xu X, Moubarak R, Myung P, Taketo M, Osman I, Nishimura E, Ito M. 1379 Cell of origin contributes to the melanoma diversity Journal of Investigative Dermatology. 138: S234. DOI: 10.1016/J.Jid.2018.03.1396 |
0.373 |
|
| 2017 |
Liu S, Tetzlaff MT, Wang T, Chen X, Yang R, Kumar SM, Vultur A, Li P, Martin JS, Herlyn M, Amaravadi R, Li B, Xu X. Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. Oncotarget. 8: 115140-115152. PMID 29383148 DOI: 10.18632/Oncotarget.22944 |
0.392 |
|
| 2017 |
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, ... ... Xu X, et al. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports. 21: 1953-1967. PMID 29141225 DOI: 10.1016/J.Celrep.2017.10.021 |
0.337 |
|
| 2017 |
Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, ... ... Xu X, et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell. 32: 654-668.e5. PMID 29136508 DOI: 10.1016/J.Ccell.2017.10.005 |
0.352 |
|
| 2017 |
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, ... ... Xu X, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 28953887 DOI: 10.1038/Nature24040 |
0.308 |
|
| 2017 |
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications. 8: 607. PMID 28928360 DOI: 10.1038/S41467-017-00452-4 |
0.391 |
|
| 2017 |
Perego M, Maurer M, Wang JX, Shaffer S, Müller AC, Parapatics K, Li L, Hristova D, Shin S, Keeney F, Liu S, Xu X, Raj A, Jensen JK, Bennett KL, et al. A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene. PMID 28925403 DOI: 10.1038/Onc.2017.341 |
0.391 |
|
| 2017 |
Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, et al. Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 32: 377-391.e9. PMID 28898698 DOI: 10.1016/J.Ccell.2017.08.004 |
0.344 |
|
| 2017 |
Ndoye A, Budina-Kolomets A, Kugel CH, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Vashisht Gopal YN, Davies MA, Mills GB, Xu X, Wu H, et al. ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma. Cancer Research. PMID 28887323 DOI: 10.1158/0008-5472.Can-17-0907 |
0.359 |
|
| 2017 |
Sinnamon AJ, Neuwirth MG, Yalamanchi P, Gimotty P, Elder DE, Xu X, Kelz RR, Roses RE, Chu EY, Ming ME, Fraker DL, Karakousis GC. Association Between Patient Age and Lymph Node Positivity in Thin Melanoma. Jama Dermatology. PMID 28724122 DOI: 10.1001/Jamadermatol.2017.2497 |
0.304 |
|
| 2017 |
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, ... ... Xu X, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. PMID 28397821 DOI: 10.1038/Nature22079 |
0.343 |
|
| 2017 |
Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, Alicea GM, Wang JX, Ghosh K, Cheng PF, Lisanti S, Marchbank K, Dang V, Levesque MP, Dummer R, ... Xu X, et al. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28232477 DOI: 10.1158/1078-0432.Ccr-17-0201 |
0.351 |
|
| 2017 |
Taylor LA, Abraham RM, Tahirovic E, van Belle P, Li B, Huang L, Elder DE, Gimotty P, Xu X. High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28106104 DOI: 10.1038/Modpathol.2016.226 |
0.353 |
|
| 2017 |
Qin S, Zhang Z, Zhao J, Xu X, Fu S, Luan Y, Xu T. Combination of Localized Radiation Therapy and Erb-IL-10 Generates Abscopal Effect by Activating CD8 + T Cells in Tumor Microenvironment International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.373 |
0.312 |
|
| 2016 |
Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Science Immunology. 1. PMID 28417112 DOI: 10.1126/Sciimmunol.Aaf8943 |
0.346 |
|
| 2016 |
Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, Chen X, Xu C, Xiang AP, Huang Q, Xu X, et al. Suppression of mir-200 family expression by oncogenic KRAS activation promotes cell survival and epithelial-mesenchymal transition in KRAS-driven cancer. Molecular and Cellular Biology. PMID 27550813 DOI: 10.1128/Mcb.00079-16 |
0.301 |
|
| 2016 |
Shannan B, Watters A, Chen Q, Mollin S, Dörr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, et al. PIM kinases as therapeutic targets against advanced melanoma. Oncotarget. PMID 27448973 DOI: 10.18632/Oncotarget.10703 |
0.402 |
|
| 2016 |
Yang R, Xu X. Isolation and Culture of Neural Crest Stem Cells from Human Hair Follicles. Methods in Molecular Biology (Clifton, N.J.). 1453: 49-55. PMID 27431246 DOI: 10.1007/978-1-4939-3786-8_7 |
0.315 |
|
| 2016 |
Gimotty PA, Shore R, Lozon N, Whitlock J, He S, Vigneau FD, Dickie L, Elder DE, Xu X, Schwartz AG, Guerry D. Miscoding of melanoma thickness in SEER: Research and clinical implications. The Journal of Investigative Dermatology. PMID 27354265 DOI: 10.1016/J.Jid.2016.05.121 |
0.312 |
|
| 2016 |
Liu W, Yang R, Payne AS, Schowalter RM, Spurgeon ME, Lambert PF, Xu X, Buck CB, You J. Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection. Cell Host & Microbe. PMID 27212661 DOI: 10.1016/J.Chom.2016.04.024 |
0.309 |
|
| 2016 |
Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, ... ... Xu X, et al. Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports. PMID 27210749 DOI: 10.1016/J.Celrep.2016.04.073 |
0.397 |
|
| 2016 |
Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Reports. PMID 27052162 DOI: 10.1016/J.Celrep.2016.03.006 |
0.381 |
|
| 2016 |
Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. The Journal of Clinical Investigation. PMID 27043285 DOI: 10.1172/Jci82661 |
0.337 |
|
| 2016 |
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, ... ... Xu X, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. PMID 27042933 DOI: 10.1038/Nature17392 |
0.364 |
|
| 2016 |
Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G, Penman E, Denstman F, Xu X, Altieri DC, Du H, Yan C, et al. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity. 44: 303-15. PMID 26885857 DOI: 10.1016/J.Immuni.2016.01.014 |
0.365 |
|
| 2016 |
Xie L, Yang R, Liu S, Lyle S, Cotsarelis G, Xiang L, Zhang L, Li B, Wan M, Xu X. TR3 is preferentially expressed by bulge epithelial stem cells in human hair follicles. Laboratory Investigation; a Journal of Technical Methods and Pathology. 96: 81-8. PMID 26707825 DOI: 10.1038/Labinvest.2015.125 |
0.626 |
|
| 2016 |
Victor CT, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Benci J, Xu B, Dada H, Odorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi R, Schuchter L, ... ... Xu X, et al. Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A056 |
0.349 |
|
| 2016 |
Huang A, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Adamow M, Kuk D, Panangeas K, Carerra C, Wong P, Quagliarello F, Pauken KE, ... ... Xu X, et al. Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr05 |
0.373 |
|
| 2016 |
Krepler C, Sproesser K, Beqiri M, Xiao M, Brafford P, Xu W, Garman B, Wargo J, Davies MA, Frederick DT, Flaherty KT, Hoon D, Bennett JJ, Guarino M, Petrelli NJ, ... ... Xu X, et al. Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A01 |
0.381 |
|
| 2016 |
Victor CT, Rech A, Benci J, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odorizzi P, Herati R, Amaravadi R, Schuchter L, Ishwaran H, Mick R, ... ... Xu X, et al. Abstract PR05: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-Pr05 |
0.337 |
|
| 2015 |
Yang S, Luo C, Gu Q, Xu Q, Wang G, Sun H, Qian Z, Tan Y, Qin Y, Shen Y, Xu X, Chen SH, Chan CC, Wang H, Mao M, et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget. PMID 26701727 DOI: 10.18632/Oncotarget.6684 |
0.32 |
|
| 2015 |
Xu MJ, Dorsey JF, Amaravadi R, Karakousis G, Simone CB, Xu X, Xu W, Carpenter EL, Schuchter L, Kao GD. Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. The Oncologist. PMID 26614709 DOI: 10.1634/Theoncologist.2015-0207 |
0.349 |
|
| 2015 |
Kong Y, Si L, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X, Cui C, Guo J. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26490311 DOI: 10.1158/1078-0432.Ccr-15-1110 |
0.306 |
|
| 2015 |
Cao J, Dai X, Wan L, Wang H, Zhang J, Goff PS, Sviderskaya EV, Xuan Z, Xu Z, Xu X, Hinds P, Flaherty KT, Faller DV, Goding CR, Wang Y, et al. The E3 ligase APC/CCdh1 promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. Science Signaling. 8: ra87. PMID 26329581 DOI: 10.1126/Scisignal.Aab1995 |
0.368 |
|
| 2015 |
Gu Q, Zhang B, Sun H, Xu Q, Tan Y, Wang G, Luo Q, Xu W, Yang S, Li J, Fu J, Chen L, Yuan S, Liang G, Ji Q, ... ... Xu X, et al. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget. PMID 26062443 DOI: 10.18632/Oncotarget.3969 |
0.302 |
|
| 2015 |
Cheng J, Li W, Kang B, Zhou Y, Song J, Dan S, Yang Y, Zhang X, Li J, Yin S, Cao H, Yao H, Zhu C, Yi W, Zhao Q, ... Xu X, et al. Tryptophan derivatives regulate the transcription of Oct4 in stem-like cancer cells. Nature Communications. 6: 7209. PMID 26059097 DOI: 10.1038/Ncomms8209 |
0.325 |
|
| 2015 |
Xu MJ, Cooke M, Steinmetz D, Karakousis G, Saxena D, Bartlett E, Xu X, Hahn SM, Dorsey JF, Kao GD. A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells. Plos One. 10: e0123376. PMID 25807549 DOI: 10.1371/Journal.Pone.0123376 |
0.344 |
|
| 2015 |
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, ... ... Xu X, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 520: 373-7. PMID 25754329 DOI: 10.1038/Nature14292 |
0.345 |
|
| 2015 |
Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine B, Amaravadi RK, Speicher DW. Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy. 11: 60-74. PMID 25484078 DOI: 10.4161/15548627.2014.984273 |
0.369 |
|
| 2015 |
Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, ... ... Xu X, et al. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell & Melanoma Research. 28: 184-95. PMID 25407936 DOI: 10.1111/Pcmr.12330 |
0.361 |
|
| 2015 |
Bajor DL, Mick R, Riese MJ, Lee RP, Xu X, Torigian DA, Stelekati E, Sweeney M, Sullivan BJ, Schuchter LM, Amaravadi R, Wherry EJ, Vonderheide RH. Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A38 |
0.344 |
|
| 2015 |
Behera R, Marchbank K, Kaur A, Dang V, Webster M, O'Connell M, Xu X, Weeraratna A. Abstract A11: Crosstalk between klotho and wnt5A drives age-related melanoma progression Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A11 |
0.352 |
|
| 2015 |
Kaur A, Marchbank K, Dang V, O'Connell M, Webster M, Appleton J, Cheng P, Valiga A, Morissette R, McDonnell N, Ferrucci L, Kossenkov A, Meeth K, Bosenberg M, Tang H, ... ... Xu X, et al. Abstract A04: Aging microenvironment modulates melanoma invasion and metastasis Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A04 |
0.349 |
|
| 2015 |
Bajor DL, Mick R, Riese MJ, Richman LP, Xu X, Torigian DA, Stelekati E, Sweeney M, Sullivan B, Schuchter LM, Amaravadi R, Wherry EJ, Vonderheide RH. Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct137 |
0.346 |
|
| 2015 |
Yang S, Luo C, Gu Q, Xu Q, Sun H, Qian Z, Tan Y, Wu H, Qin Y, Shen Y, Xu X, Chen S, Chan C, Wang H, Mao M, et al. Abstract 688: Activating JAK1-S703I mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma patient-derived xenograft tumor models Cancer Research. 75: 688-688. DOI: 10.1158/1538-7445.Am2015-688 |
0.334 |
|
| 2015 |
Vultur AM, Shannan B, Chen Q, Watters A, Mollin S, Meggers E, Krepler C, Perego M, Li L, Gimotty PA, Xu X, Herlyn M. Abstract 687: Compound screen identifies PIM kinases as therapeutic targets for melanoma Cancer Research. 75: 687-687. DOI: 10.1158/1538-7445.Am2015-687 |
0.364 |
|
| 2015 |
Rech AJ, Victor CT, Maity A, Rengan R, Pauken KE, Stelekati E, Benci J, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, ... ... Xu X, et al. Abstract 2858: Radiation and dual immune checkpoint blockade overcome tumor resistance and distinctly improve immunity Cancer Research. 75: 2858-2858. DOI: 10.1158/1538-7445.Am2015-2858 |
0.379 |
|
| 2015 |
Krepler C, Xiao M, Sproesser K, Brafford P, Shannan B, Beqiri M, Xu W, Garman B, Nathanson KL, Xu X, Karakousis G, Mills GB, Lu Y, Caponigro G, Boehm M, et al. Abstract 2842: Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target Cancer Research. 75: 2842-2842. DOI: 10.1158/1538-7445.Am2015-2842 |
0.36 |
|
| 2015 |
Behera R, Kaur A, Marchbank K, Dang V, Webster M, Xu X, Weeraratna AT. Abstract 1556: Role of Klotho in age-related melanoma progression Cancer Research. 75: 1556-1556. DOI: 10.1158/1538-7445.Am2015-1556 |
0.359 |
|
| 2014 |
Yang R, Zheng Y, Li L, Liu S, Burrows M, Wei Z, Nace A, Herlyn M, Cui R, Guo W, Cotsarelis G, Xu X. Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors. Nature Communications. 5: 5807. PMID 25510211 DOI: 10.1038/Ncomms6807 |
0.615 |
|
| 2014 |
Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunology Research. 2: 1051-8. PMID 25252722 DOI: 10.1158/2326-6066.Cir-14-0154 |
0.371 |
|
| 2014 |
Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. The Journal of Clinical Investigation. 124: 1406-17. PMID 24569374 DOI: 10.1172/Jci70454 |
0.345 |
|
| 2014 |
Yang R, Zheng Y, Burrows M, Liu S, Wei Z, Nace A, Guo W, Kumar S, Cotsarelis G, Xu X. Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells. Nature Communications. 5: 3071. PMID 24468981 DOI: 10.1038/Ncomms4071 |
0.608 |
|
| 2014 |
Xu X, Gimotty PA, Guerry D, Karakousis G, Elder DE. Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma. Methods in Molecular Biology (Clifton, N.J.). 1102: 275-86. PMID 24258984 DOI: 10.1007/978-1-62703-727-3_15 |
0.337 |
|
| 2014 |
Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, Vogt T, Xu X, Hwang WT, Lieu M, Belser E, Liu R, Somasundaram R, et al. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. The Journal of Investigative Dermatology. 134: 1108-18. PMID 24157461 DOI: 10.1038/Jid.2013.437 |
0.366 |
|
| 2014 |
Kumar SM, Dai J, Li S, Yang R, Yu H, Nathanson KL, Liu S, Zhou H, Guo J, Xu X. Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation. Oncogene. 33: 832-41. PMID 23334329 DOI: 10.1038/Onc.2012.642 |
0.395 |
|
| 2014 |
Yopp A, Kallinteris N, Huang X, Shan J, Menander K, Hutchins J, King S, Xu X, Gabrilovich D, Brekken R. Correlative studies of a Phase II clinical study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma Journal For Immunotherapy of Cancer. 2: P214. DOI: 10.1186/2051-1426-2-S3-P214 |
0.32 |
|
| 2014 |
Akl A, Xu X, Piao S, Amaravadi RK, Speicher DW. Abstract 310: Identification of secreted proteins that reflect intracellular autophagy dynamics in melanoma Cancer Research. 74: 310-310. DOI: 10.1158/1538-7445.Am2014-310 |
0.353 |
|
| 2013 |
Lu H, Liu J, Liu S, Zeng J, Ding D, Carstens RP, Cong Y, Xu X, Guo W. Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion. Developmental Cell. 27: 560-73. PMID 24331928 DOI: 10.1016/J.Devcel.2013.10.020 |
0.348 |
|
| 2013 |
Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, ... ... Xu X, et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Reports. 4: 1090-9. PMID 24055054 DOI: 10.1016/J.Celrep.2013.08.023 |
0.338 |
|
| 2013 |
Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL, Diehl JA. The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Molecular and Cellular Biology. 33: 4422-33. PMID 24019069 DOI: 10.1128/Mcb.00706-13 |
0.327 |
|
| 2013 |
Cintolo JA, Gimotty P, Blair A, Guerry D, Elder DE, Hammond R, Elenitsas R, Xu X, Fraker D, Schuchter LM, Czerniecki BJ, Karakousis G. Local immune response predicts survival in patients with thick (t4) melanomas. Annals of Surgical Oncology. 20: 3610-7. PMID 23838911 DOI: 10.1245/S10434-013-3086-3 |
0.344 |
|
| 2013 |
Gerami P, Cooper C, Bajaj S, Wagner A, Fullen D, Busam K, Scolyer RA, Xu X, Elder DE, Abraham RM, Prieto VG, Guitart J, Liu P, Pestova E, Barnhill RL. Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. The American Journal of Surgical Pathology. 37: 1387-94. PMID 23797719 DOI: 10.1097/Pas.0B013E31828Fc283 |
0.323 |
|
| 2013 |
Karakousis G, Yang R, Xu X. Circulating melanoma cells as a predictive biomarker. The Journal of Investigative Dermatology. 133: 1460-2. PMID 23673501 DOI: 10.1038/Jid.2013.34 |
0.382 |
|
| 2013 |
Yang R, Xu X. Isolation and culture of neural crest stem cells from human hair follicles. Journal of Visualized Experiments : Jove. PMID 23608752 DOI: 10.3791/3194 |
0.34 |
|
| 2013 |
Abraham RM, Karakousis G, Acs G, Ziober AF, Cerroni L, Mihm MC, Elder DE, Xu X. Lymphatic invasion predicts aggressive behavior in melanocytic tumors of uncertain malignant potential (MELTUMP). The American Journal of Surgical Pathology. 37: 669-75. PMID 23552384 DOI: 10.1097/Pas.0B013E318288Ff47 |
0.353 |
|
| 2013 |
Abel EV, Basile KJ, Kugel CH, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. The Journal of Clinical Investigation. 123: 2155-68. PMID 23543055 DOI: 10.1172/Jci65780 |
0.357 |
|
| 2013 |
Sargen MR, Gormley RH, Pasha TL, Yum S, Acs G, Xu X, Zhang PJ. Melanocytic tumors express connexin 43 but not 26: immunohistochemical analysis with potential significance in melanocytic oncogenesis. The American Journal of Dermatopathology. 35: 813-7. PMID 23344009 DOI: 10.1097/Dad.0B013E318278D401 |
0.37 |
|
| 2013 |
Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang WT, Gelfand JM, Whalen FM, Elenitsas R, Xu X, Schmults CD. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. Jama Dermatology. 149: 402-10. PMID 23325457 DOI: 10.1001/Jamadermatol.2013.2456 |
0.333 |
|
| 2013 |
Haider SA, Zou W, Xu X, Balasubramanian S, Wu A, Yue NJ, Haffty BG, Jabbour SK. Correlation of Survival to CBCT-Based Tumor Response During Chemoradiation in Patients With Stage III Non-Small Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.1430 |
0.315 |
|
| 2012 |
Lin Y, Yang Y, Li W, Chen Q, Li J, Pan X, Zhou L, Liu C, Chen C, He J, Cao H, Yao H, Zheng L, Xu X, Xia Z, et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Molecular Cell. 48: 627-40. PMID 23041284 DOI: 10.1016/J.Molcel.2012.08.030 |
0.312 |
|
| 2012 |
Deng Z, Wang Z, Xiang C, Molczan A, Baubet V, Conejo-Garcia J, Xu X, Lieberman PM, Dahmane N. Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. Journal of Cell Science. 125: 4383-94. PMID 22641694 DOI: 10.1242/Jcs.108118 |
0.329 |
|
| 2012 |
Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X. Loss of microRNA-205 expression is associated with melanoma progression. Laboratory Investigation; a Journal of Technical Methods and Pathology. 92: 1084-96. PMID 22525428 DOI: 10.1038/Labinvest.2012.62 |
0.325 |
|
| 2012 |
Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu X, Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell & Melanoma Research. 25: 493-505. PMID 22498258 DOI: 10.1111/J.1755-148X.2012.01005.X |
0.345 |
|
| 2012 |
Dong D, Jiang M, Xu X, Guan M, Wu J, Chen Q, Xiang L. The effects of NB-UVB on the hair follicle-derived neural crest stem cells differentiating into melanocyte lineage in vitro. Journal of Dermatological Science. 66: 20-8. PMID 22391242 DOI: 10.1016/J.Jdermsci.2012.01.012 |
0.342 |
|
| 2012 |
Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W, Xu X. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 31: 4898-911. PMID 22286766 DOI: 10.1038/Onc.2011.656 |
0.433 |
|
| 2012 |
Xu X, Chen L, Guerry D, Dawson PR, Hwang WT, VanBelle P, Elder DE, Zhang PJ, Ming ME, Schuchter L, Gimotty PA. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 229-37. PMID 22096024 DOI: 10.1158/1078-0432.Ccr-11-0490 |
0.317 |
|
| 2012 |
Ferenczi K, Lastra RR, Farkas T, Elenitsas R, Xu X, Roberts S, Brooks JS, Zhang PJ. MUM-1 expression differentiates tumors in the PEComa family from clear cell sarcoma and melanoma. International Journal of Surgical Pathology. 20: 29-36. PMID 21903680 DOI: 10.1177/1066896911418204 |
0.419 |
|
| 2012 |
Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, Acs G, Xu X. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 31: 1649-60. PMID 21860424 DOI: 10.1038/Onc.2011.366 |
0.436 |
|
| 2012 |
Ge Y, Azuma R, Gekonge B, Lopez-Coral A, Xiao M, Zhang G, Xu X, Montaner LJ, Wei Z, Herlyn M, Wang T, Kaufman RE. Induction of metallothionein expression during monocyte to melanoma-associated macrophage differentiation Frontiers in Biology. 7: 359-367. DOI: 10.1007/S11515-012-1237-8 |
0.346 |
|
| 2011 |
Liu S, Yu H, Kumar SM, Martin JS, Bing Z, Sheng W, Bosenberg M, Xu X. Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway. Cancer Biology & Therapy. 12: 1005-14. PMID 22123174 DOI: 10.4161/Cbt.12.11.18380 |
0.383 |
|
| 2011 |
Liu S, Kumar SM, Martin JS, Yang R, Xu X. Snail1 mediates hypoxia-induced melanoma progression. The American Journal of Pathology. 179: 3020-31. PMID 21996677 DOI: 10.1016/J.Ajpath.2011.08.038 |
0.414 |
|
| 2011 |
Yang R, Jiang M, Kumar SM, Xu T, Wang F, Xiang L, Xu X. Generation of melanocytes from induced pluripotent stem cells. The Journal of Investigative Dermatology. 131: 2458-66. PMID 21833016 DOI: 10.1038/Jid.2011.242 |
0.342 |
|
| 2011 |
Yun SJ, Gimotty PA, Hwang WT, Dawson P, Van Belle P, Elder DE, Elenitsas R, Schuchter L, Zhang PJ, Guerry D, Xu X. High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma. The American Journal of Surgical Pathology. 35: 235-42. PMID 21263244 DOI: 10.1097/Pas.0B013E3182036Ccd |
0.309 |
|
| 2011 |
Liu S, Yu H, Kumar S, Martin J, Xu X. Abstract 5043: Norcantharidin induces melanoma cell apoptosis through TR3 pathway Cancer Research. 71: 5043-5043. DOI: 10.1158/1538-7445.Am2011-5043 |
0.362 |
|
| 2011 |
Baumann B, Dorsey J, Xu X, Harada T, Chapman C, Benci J, Jaiswal S, Mahmud A, Discher D, Kao G. ‘Breaking through the Tumor BBB’: Enhancing the Efficacy of Nanobiopolymer Therapeutics against Intracranial Tumors with Targeted Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 81: S145-S146. DOI: 10.1016/J.Ijrobp.2011.06.298 |
0.306 |
|
| 2010 |
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18: 683-95. PMID 21156289 DOI: 10.1016/J.Ccr.2010.11.023 |
0.318 |
|
| 2010 |
Kong Y, Kumar SM, Xu X. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Archives of Pathology & Laboratory Medicine. 134: 1740-9. PMID 21128770 DOI: 10.1043/2009-0418-Rar.1 |
0.302 |
|
| 2010 |
Xu X, Zhong JF. Circulating tumor cells and melanoma progression. The Journal of Investigative Dermatology. 130: 2349-51. PMID 20842140 DOI: 10.1038/Jid.2010.215 |
0.383 |
|
| 2010 |
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, ... ... Xu X, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 467: 596-9. PMID 20823850 DOI: 10.1038/Nature09454 |
0.334 |
|
| 2010 |
Li L, Fukunaga-Kalabis M, Yu H, Xu X, Kong J, Lee JT, Herlyn M. Human dermal stem cells differentiate into functional epidermal melanocytes. Journal of Cell Science. 123: 853-60. PMID 20159965 DOI: 10.1242/Jcs.061598 |
0.353 |
|
| 2010 |
Yu H, Kumar SM, Kossenkov AV, Showe L, Xu X. Stem cells with neural crest characteristics derived from the bulge region of cultured human hair follicles. The Journal of Investigative Dermatology. 130: 1227-36. PMID 19829300 DOI: 10.1038/Jid.2009.322 |
0.326 |
|
| 2009 |
Yun S, Gimotty P, Hwang W, Dawson P, VanBelle P, Elder D, Elenitsas R, Guerry D, Schuchter L, Xu X. The biology and prognostic value of lymphatic vessel density (LD) and lymphatic invasion (LI) in regression in melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9017. PMID 27962378 DOI: 10.1200/Jco.2009.27.15_Suppl.9017 |
0.32 |
|
| 2009 |
Xu X, Chen L, Hwang W, Dawson P, Guerry D, VanBelle P, Elder D, Schuchter L, Gimotty P. The prognostic significance of lymphatic invasion in primary melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9050. PMID 27962127 DOI: 10.1200/Jco.2009.27.15_Suppl.9050 |
0.314 |
|
| 2009 |
Gimotty P, Guerry D, VanBelle P, Montone K, Guerra M, Hwang W, Schuchter L, Xu X, Elder D. Ki67 as a prognostic biomarker for patients with vertical growth phase (VGP) melanomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9043. PMID 27962110 DOI: 10.1200/Jco.2009.27.15_Suppl.9043 |
0.373 |
|
| 2009 |
Thieu KP, Rosenbach M, Xu X, Kist JM. Neutrophilic dermatosis complicating lenalidomide therapy. Journal of the American Academy of Dermatology. 61: 709-710. PMID 19577327 DOI: 10.1016/J.Jaad.2008.12.011 |
0.301 |
|
| 2009 |
Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. The American Journal of Pathology. 174: 2367-77. PMID 19389934 DOI: 10.2353/Ajpath.2009.081057 |
0.36 |
|
| 2009 |
Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X, Acs G. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. The American Journal of Pathology. 174: 1504-14. PMID 19264915 DOI: 10.2353/Ajpath.2009.080592 |
0.387 |
|
| 2009 |
Xu X, Zhang PJ, Elder DE. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Archives of Pathology & Laboratory Medicine. 127: 1083-1085. PMID 12951966 DOI: 10.1043/1543-2165(2003)127<1083A:Ltte>2.0.Co;2 |
0.325 |
|
| 2008 |
Xu X, Gimotty PA, Guerry D, Karakousis G, Van Belle P, Liang H, Montone K, Pasha T, Ming ME, Acs G, Feldman M, Barth S, Hammond R, Elenitsas R, Zhang PJ, et al. Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Human Pathology. 39: 901-9. PMID 18440591 DOI: 10.1016/J.Humpath.2007.10.017 |
0.361 |
|
| 2008 |
Edwards R, Guerry D, Piris A, Elenitsas R, Seykora J, Schuchter L, Mihm M, Xu X, Gimotty P. Phospho-ERK (pERK) and Ki67 expression as compared to thickness and mitotic rate (MR) as prognostic factors in patients with stage I/II melanomas Journal of Clinical Oncology. 26: 9020-9020. DOI: 10.1200/Jco.2008.26.15_Suppl.9020 |
0.397 |
|
| 2008 |
Sariya D, Adams-McDonnell R, Cusack C, Xu X, Elenitsas R, Seykora J, Pasha T, Zhang P, Baldassano M, Lessin S, Wu H. Cutaneous Metastasis: A Single Institution Clinical and Histopathologic Experience Journal of Cutaneous Pathology. 32: 114-114. DOI: 10.1111/J.0303-6987.2005.320Gm.X |
0.351 |
|
| 2008 |
Kucher C, Xu X, Pasha T, Elenitsas R. Histologic Comparison of Scleromyxedema and Nephrogenic Fibrosing Dermopathy Journal of Cutaneous Pathology. 32: 99-99. DOI: 10.1111/J.0303-6987.2005.320Dw.X |
0.315 |
|
| 2007 |
Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Research. 67: 3177-84. PMID 17409425 DOI: 10.1158/0008-5472.Can-06-3312 |
0.347 |
|
| 2007 |
Yu H, Kumar SM, Fang D, Acs G, Xu X. Nuclear orphan receptor TR3/Nur77 mediates melanoma cell apoptosis. Cancer Biology & Therapy. 6: 405-12. PMID 17297306 DOI: 10.4161/Cbt.6.3.3755 |
0.375 |
|
| 2007 |
Liang H, Wu H, Giorgadze TA, Sariya D, Bellucci KS, Veerappan R, Liegl B, Acs G, Elenitsas R, Shukla S, Youngberg GA, Coogan PS, Pasha T, Zhang PJ, Xu X. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. The American Journal of Surgical Pathology. 31: 304-10. PMID 17255777 DOI: 10.1097/01.Pas.0000213388.47913.F1 |
0.33 |
|
| 2007 |
Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ. Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma. The American Journal of Surgical Pathology. 31: 129-40. PMID 17197929 DOI: 10.1097/01.Pas.0000213316.59176.9B |
0.345 |
|
| 2006 |
Kumar SM, Yu H, Fong D, Acs G, Xu X. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Research. 16: 275-83. PMID 16845323 DOI: 10.1097/01.Cmr.0000222594.60611.C3 |
0.361 |
|
| 2006 |
Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G, Herlyn M, Xu X. Isolation of a novel population of multipotent adult stem cells from human hair follicles. The American Journal of Pathology. 168: 1879-88. PMID 16723703 DOI: 10.2353/Ajpath.2006.051170 |
0.327 |
|
| 2006 |
Fang D, Leishear K, Nguyen TK, Finko R, Cai K, Fukunaga M, Li L, Brafford PA, Kulp AN, Xu X, Smalley KS, Herlyn M. Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells (Dayton, Ohio). 24: 1668-77. PMID 16574754 DOI: 10.1634/Stemcells.2005-0414 |
0.334 |
|
| 2006 |
Dumoff KL, Chu CS, Harris EE, Holtz D, Xu X, Zhang PJ, Acs G. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 19: 708-16. PMID 16528371 DOI: 10.1038/Modpathol.3800580 |
0.326 |
|
| 2005 |
Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clinical Cancer Research. 11: 8364-8371. PMID 16322297 DOI: 10.1158/1078-0432.Ccr-05-1238 |
0.336 |
|
| 2005 |
Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8048-56. PMID 16258103 DOI: 10.1200/Jco.2005.02.0735 |
0.371 |
|
| 2005 |
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research. 65: 9328-37. PMID 16230395 DOI: 10.1158/0008-5472.Can-05-1343 |
0.385 |
|
| 2005 |
Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. The American Journal of Pathology. 166: 823-30. PMID 15743794 DOI: 10.1016/S0002-9440(10)62303-6 |
0.413 |
|
| 2005 |
Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, Acs G. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 18: 97-104. PMID 15467716 DOI: 10.1038/Modpathol.3800269 |
0.347 |
|
| 2004 |
Kucher C, Zhang PJ, Pasha T, Elenitsas R, Wu H, Ming ME, Elder DE, Xu X. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. The American Journal of Dermatopathology. 26: 452-7. PMID 15618925 DOI: 10.1097/00000372-200412000-00002 |
0.368 |
|
| 2004 |
Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion Pathology. 36: 428-434. PMID 15370112 DOI: 10.1080/00313020412331283905 |
0.306 |
|
| 2004 |
Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Letters. 214: 243-51. PMID 15363551 DOI: 10.1016/J.Canlet.2004.04.027 |
0.361 |
|
| 2004 |
Xu X, Bellucci KSW, Elenitsas R, Elder DE. Cellular nodules in congenital pattern nevi. Journal of Cutaneous Pathology. 31: 153-159. PMID 14690460 DOI: 10.1111/J.0303-6987.2004.00156.X |
0.333 |
|
| 2003 |
Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene. 22: 6891-9. PMID 14534536 DOI: 10.1038/Sj.Onc.1206819 |
0.391 |
|
| 2003 |
Xu X, Solky B, Elenitsas R, Cotsarelis G. Scarring alopecia associated with mastocytosis. Journal of Cutaneous Pathology. 30: 561-5. PMID 14507404 DOI: 10.1034/J.1600-0560.2003.00093.X |
0.552 |
|
| 2003 |
Xu X, Lyle S, Liu Y, Solky B, Cotsarelis G. Differential expression of cyclin D1 in the human hair follicle. The American Journal of Pathology. 163: 969-78. PMID 12937137 DOI: 10.1016/S0002-9440(10)63456-6 |
0.608 |
|
| 2002 |
Xu X, Genega EM, Nasuti JF. Differential immunocytochemical staining patterns of uroplakin observed on neoplastic and nonneoplastic tissue fragments obtained from upper urinary tract brush specimens. Acta Cytologica. 46: 684-689. PMID 12146031 DOI: 10.1159/000326976 |
0.311 |
|
| 2002 |
Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. The American Journal of Surgical Pathology. 26: 82-7. PMID 11756773 DOI: 10.1097/00000478-200201000-00010 |
0.341 |
|
| 2000 |
Xu X, Roberts SA, Pasha TL, Zhang PJ. Undesirable cytokeratin immunoreactivity of native nonepithelial cells in sentinel lymph nodes from patients with breast carcinoma Archives of Pathology and Laboratory Medicine. 124: 1310-1313. PMID 10975928 DOI: 10.1043/0003-9985(2000)124<1310:Ucionn>2.0.Co;2 |
0.321 |
|
| Show low-probability matches. |